Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The objective of this study was to explore the efficacy of combination therapy with citalopram plus omega-3 fatty acids versus citalopram plus placebo (olive oil) in the initial treatment of individuals with major depressive disorder (MDD). We hypothesized that combination therapy would lead not only to greater efficacy but also to a more rapid onset of therapeutic response. METHODS: Forty-two subjects participated in this 9-week randomized, masked, placebo-controlled study of combination therapy (two 1 g capsules containing a blend of 900 mg of eicosapentaenoic acid, 200 mg of and docosahexaenoic acid, and 100 mg of other omega-3 fatty acids twice daily plus citalopram) versus monotherapy (two 1 g capsules of olive oil per day plus citalopram) treatment of MDD. RESULTS: The combination therapy demonstrated significantly greater improvement in Hamilton Depression Rating scale scores over time (F = 7.32; df 1,177; P = 0.008) beginning at week 4 (t = -2.48; df 177; P = 0.014). CONCLUSIONS: Combination therapy was more effective than monotherapy in decreasing signs and symptoms of MDD during the 8 weeks of active treatment; however, combination therapy did not seem to enhance the speed of the initial antidepressant response. These findings suggest that there may be an advantage to combining omega-3 fatty acids with a selective serotonin uptake inhibitor in the initial treatment of individuals with MDD. A larger definitive study is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, a meta-analysis has shown that rTMS is inferior to ECT with regard to efficacy in TRD 188 .”
From Major depressive disorder (2016) · cites this paper as [188]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391 · cited 1×
“The estimated lifetime incidence of MDD in adults in the United States is more than 15%.(3) In 2000, the economic burden of depressive disorders in the United States was an estimated $83.”
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
(1976) · Medical Entomology and Zoology · Cited by 8,899
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 1×
“Exclusion criteria were: (1) diagnosis of psychotic disorders including psychotic depression and bipolar disorders; (2) current drug or alcohol abuse or dependence, or history of drug or alcohol abuse or dependence within the previous six months; (3) unstable medical or neurological conditions that were likely to inte…”
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“Exclusion criteria were: (1) diagnosis of psychotic disorders including psychotic depression and bipolar disorders; (2) current drug or alcohol abuse or dependence, or history of drug or alcohol abuse or dependence within the previous six months; (3) unstable medical or neurological conditions that were likely to inte…”
The ESEMeD/MHEDEA 2000 Investigators, Alonso, J., Angermeyer, M. C., Bernert, S., Bruffaerts, R., Brugha, T. S., Bryson, H., de Girolamo, G., de Graaf, R., Demyttenaere, K., et al. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0047.2004.00327.x · Cited by 1,819 · cited 1×
“Major depressive disorder (MDD) is the most prevalent Axis I disorder and one of the leading causes of disability in the United States and worldwide.(1,2) The estimated lifetime incidence of MDD in adults in the United States is more than 15%.”
The Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280
Nemets, B., Stahl, Z., & Belmaker, R. H. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.477 · Cited by 627
Peet, M., & Horrobin, D. F. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.913 · Cited by 614
Research works printed but not linked: 1
- Beck AT. Depression Inventory. Center for Cognitive Therapy; Philadelphia: 1978. [Google Scholar]
Cited by
Items 101–162 of 162
Norouziasl, R., Zeraattalab-Motlagh, S., Jayedi, A., & Shab‐Bidar, S. (2023) · British Journal Of Nutrition · doi:10.1017/s0007114523002052 · Cited by 25
McNamara, R. K., Able, J. A., Liu, Y., Jandacek, R. J., Rider, T., Tso, P., & Lipton, J. W. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.09.010 · Cited by 18
“Importantly, adjunctive LCn-3 fatty acid supplementation has also been found to significantly augment the antidepressant effects of SSRIs in patients with MDD (Jazayeri et al., 2008; Gertsik et al., 2012; Peet and Horrobin, 2002).”
BackgroundInfluentialChukaew, P., Leow, A., Saengsawang, W., & Rasenick, M. M. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0724-6 · Cited by 23
“serotonin reuptake inhibitors (SSRIs) and n-3 PUFAs augmented treatment efficacy in depression [24-26].”
Backgroundω-3 and major depression: a review
de Mello, A. H., Gassenferth, A., de Souza, L. R., Fortunato, J. J., & Rezin, G. T. (2013) · Acta Neuropsychiatrica · doi:10.1017/neu.2013.52 · Cited by 18
“(7) has explored the efficacy of the combination therapy between citalopram and v-3, comparing the citalopram associated with placebo in the initial treatment of 42 individuals with major depression, and it was v-3 and major depression”
BackgroundEffects of omega-3 on behavioral and biochemical parameters in rats submitted to chronic mild stress
de Mello, A. H., Gassenferth, A., Schraiber, R. D. B., Souza, L. D. R., Florentino, D., Danielski, L. G., Soares, E. D. C. C., Fortunato, J. J., Petronilho, F. C., Quevedo, J., et al. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9577-5 · Cited by 18
Steyn, S. F., Harvey, B. H., & Brink, C. B. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.05.021 · Cited by 18
Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses
Sarris, J. J., Murphy, J., Mischoulon, D., Papakostas, G. I., Fava, M., Berk, M., & Ng, C. H. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.16304 · Cited by 15
Berger, G. E. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5080069 · Cited by 15
“Primary diagnosis of adult major depressive disorders (MDD) [2–16]”
BackgroundImpact of Heart-Rate Variability Biofeedback on Major Depression Disorder in Resting-State fMRI
Caldwell, H. W. (2015) · ScholarsArchive (Brigham Young University) · Cited by 10
Five potential therapeutic agents as antidepressants: a brief review and future directions
Wang, S., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1071192 · Cited by 10
“One of the above studies specifically investigated whether w-3 PUFA supplementation to the SSRI, citalopram, led to an accelerated response to the antidepressant [81].”
ResultPolyunsaturated fatty acids moderate the effect of poor sleep on depression risk
Lotrich, F. E., Sears, B., & McNamara, R. K. (2015) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2015.10.004 · Cited by 9
“Although LCn-3 fatty acids have antidepressant properties [37] and may augment SSRI antidepressant effects [38,39] it is not known how or whether LCn-3 fatty acid biostatus and MDD history interact to modify IFN-MDD risk.”
Jeremiah, O. J., Cousins, G., Boland, F., Kirby, B. P., & Ryan, B. K. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e04845 · Cited by 11
“, 2015), HAM-D score of 7 (Gertsik et al., 2012; Miyaoka et al., 2018; Mota-Pereira et al., 2011), 'very much improved' on CGI (clinical global impression) scale plus scores on MADRS 10 or HAM-D 7 or BDI 9 (Siwek et al.”
BackgroundInfluentialNovel Therapeutic Targets for Major Depressive Disorder
Lazar, M. A., & McIntyre, R. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00034-2 · Cited by 10
What’s around the corner in the niche of psychopharmacotherapy of major depressive disorder?
Moodliar‐Rensburg, S., & Naguy, A. (2019) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2019.09.033 · Cited by 9
Lithium, Thyroid Hormones and Further Augmentation Strategies in Treatment‐resistant Depression
Haußmann, R., & Bauer, M. (2013) · Wiley eBooks · doi:10.1002/9781118556719.ch6 · Cited by 7
Frost, R., Zamri, A., Mathew, S., Salame, A., Bhanu, C., Bhamra, S. K., Bazo‐Alvarez, J. C., Heinrich, M., & Walters, K. R. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1609605 · Cited by 7
Kohatsu, W., & Karpowicz, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35868-2.00088-8 · Cited by 7
Hosseini, F., Khakpai, F., Fazli‐Tabaei, S., Nasehi, M., & Zarrindast, M. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.137688 · Cited by 5
Kheirabadi, G. R., Yousefian, Z., Zargar, F., Bahrami, M., & Maracy, M. R. (2020) · Journal of Education and Health Promotion · doi:10.4103/jehp.jehp_193_19 · Cited by 7
“These findings are in accordance with those of previous studies.[13,33,34]”
ResultFendt-Newlin, M., & Webber, M. (2015) · European Journal of Social Work · doi:10.1080/13691457.2015.1025710 · Cited by 5
Moyad, M. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-23422-9_7 · Cited by 5
Something fishy: The issue of omega-3 blinding in psychiatric clinical trials
Liu, J. C., Ang, R. P.-H., & Fung, D. S. S. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412451343 · Cited by 5
“Of note, in several published psychiatric trials (e.g. Gertsik et al., 2012; Grenyer et al., 2007), no apparent effort was made to match the placebo by taste: in these trials, the placebo was simply a different type of oil (e.g. safflower oil, olive oil), which would match the active omega-3 by…”
BackgroundAcylcarnitines are associated with lower depressive symptomatology in a mainland puerto rican cohort
Palacios, N., Bhupathiraju, S. N., Kelly, R. S., Lee, J. S., Ordovás, J. M., & Tucker, K. L. (2024) · Metabolomics · doi:10.1007/s11306-024-02116-z · Cited by 4
“Altered lipid profiles, particularly lower concentrations of n-3 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA) and doco-sahexaenoic acid (DHA), (Gertsik et al., 2012; Lin et al., 2010) have been observed in depressed individuals.”
Adjunctive Docosahexaenoic Acid in Residual Symptoms of Depression and Anxiety
Piperoglou, M., Hopwood, M., & Norman, T. R. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001767 · Cited by 6
Patsalos, O., Mavrogiannidis, T., Dalton, B., Field, C. J., & Himmerich, H. (2020) · Psychiatria Danubina · doi:10.24869/psyd.2020.55 · Cited by 4
“Furthermore, adjunctive treatment with -3 LCPUFAs was found to augment the therapeutic efficacy of fluoxetine (Jazayeri et al. 2008) and citalopram (Gertsik et al. 2012).”
BackgroundPolyunsaturated Fatty Acids Play a Role in Depression: Main Action Mechanisms
Mendes, J. (2014) · Journal of Biosafety & Health Education · doi:10.4172/2332-0893.1000e115 · Cited by 3
“It was suggested an advantage to combining omega-3 fatty acids with a selective serotonin uptake inhibitor in the initial treatment of individuals with major depressive disorder [12].”
BackgroundShet, D., Kumar, N. A., Gokul, M., Kini, R. D., Marathe, A., Kollampare, S., & Blossom, V. (2023) · Open Veterinary Journal · doi:10.5455/ovj.2023.v13.i4.9 · Cited by 5
“The influential role of omega-3 fatty acids on various functions of the brain has been well documented in the literature (Gertsik et al., 2012).”
BackgroundPolyunsaturated Fatty Acids in Adult Psychiatric Disorders: A Comprehensive Overview
Saah, T. C., Garlow, S. J., & Rapaport, M. H. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13602-8_18 · Cited by 3
Self-citationAntidepressant and anxiolytic effects of cod liver oil in rats.
Perveen, T., Razi, F., Haider, S., Qayyum, H., & Haleem, D. J. (2013) · Pakistan Veterinary Journal · Cited by 3
The hypothalamic-pituitary-adrenal axis in bipolar disorder
Trinetti, J., Sforzini, L., & Pariante, C. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819182-8.00024-7 · Cited by 2
Ielmini, M., Caselli, I., Ceccon, F., Diurni, M., Poloni, N., & Callegari, C. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4416 · Cited by 4
Integrative and Complementary Medicine in Psychiatry
Sarris, J. J., Gerbarg, P. L., Brown, R. P., & Muskin, P. R. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch110 · Cited by 4
Gartlehner, G., Wagner, G., Lux, L. J., Affengruber, L., Dobrescu, A. I., Kaminski-Hartenthaler, A., & Viswanathan, M. (2019) · doi:10.23970/ahrqepcmethmachinedistiller · Cited by 3
Plasma Phospholipid Polyunsaturated Fatty Acid Associations with Neurocognition
Ling, J., Keilp, J. G., Galfalvy, H., Cardino, V. N., Ahmed, A., Burke, A. K., Fenton, J. I., Mann, J. J., & Sublette, M. E. (2023) · Nutrients · doi:10.3390/nu15214542 · Cited by 3
Nutraceuticals in the Treatment of Major Depressive Disorder
Davis, A., Pence, J., & Bloomer, R. J. (2025) · Nutraceuticals · doi:10.3390/nutraceuticals5030027 · Cited by 3
“In another adjunctive study, Gertsik (2012) evaluated the effectiveness over 8 weeks of 900 mg EPA + 200 mg DHA + 100 mg other omega-3 fatty acids + 20 g citalopram versus antidepressant monotherapy control, 2 g olive oil + 20 g citalopram [68].”
The role of olive oil and its constituents in mental health: a scoping review
Eedy, V., & Aucoin, M. (2024) · British Journal Of Nutrition · doi:10.1017/s000711452400299x · Cited by 3
Role of Dietary Fatty Acids in Mood Disorders
McNamara, R. K. (2016) · Elsevier eBooks · doi:10.1016/b978-1-63067-036-8.00014-7 · Cited by 2
An Analysis of Blinding Success in a Randomised Controlled Trial of Fish Oil Omega-3 Fatty Acids
Liu, J. C., Raine, A., Ang, R. P.-H., & Fung, D. S. S. (2015) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v44n3p85 · Cited by 2
Cognitive Enhancers for the Treatment of Anxiety Disorders
Curtiss, J. E., Carpenter, J. K., Kind, S., & Hofmann, S. G. (2016) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780199935291.013.15 · Cited by 2
Inflammation-induced depression : Studying the role of proinflammatory cytokines in anhedonia
van Heesch, F. (2014) · Utrecht University Repository (Utrecht University) · Cited by 13
Diet and depression : an epidemiological study
Ruusunen, A. A. (2013) · UEF eRepo (University of Eastern Finland) · Cited by 42
Blue Food Consumption and Its Relation to Nutrient Intake among Koreans
Suk, Y., Lee, M.-J., & Ham, S. (2024) · Nutrients · doi:10.3390/nu16183128 · Cited by 1
“The intake of EPA and DHA has been associated with the prevention of cardiovascular diseases [16–18] and cognitive impairments [19], lower depression and anxiety rates [20,21], and protection against metabolic disorders throughout life [22].”
BackgroundVittalrao, A. M., Agarwal, S., Kumari, M., & Poojar, B. (2019) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/1777 · Cited by 1
어패류의 구매 및 소비 패턴에 따른 소비자 영양, 위생, 안전 인식 분석
석, 용., 이, 민., 민, 성., 채, 선., & Ham, S. (2023) · 한국식품조리과학회지 · doi:10.9724/kfcs.2023.39.4.288 · Cited by 1
Song, L., Yoshida, S., Tanaka‐Mizuno, S., Ogawa, Y., Furukawa, T. A., & Kawakami, K. (2017) · Journal of Nutrition & Intermediary Metabolism · doi:10.1016/j.jnim.2017.08.001 · Cited by 2
Long-Chain Omega-3 Fatty Acids in Child and Adolescent Psychiatry: I. Phenomenology
Strawn, J. R., Patino, R. L., Schneider, M. R., DelBello, M. P., & McNamara, R. K. (2013) · Child and Adolescent Psychopharmacology News · doi:10.1521/capn.2013.18.5.1 · Cited by 1
Rinaudo, L., & Hopwood, M. (2015) · Advances in Integrative Medicine · doi:10.1016/j.aimed.2015.02.004
Omega-3 Fatty Acids: A Review of Its Wide Range of Applications and Possible Mechanisms of Action
Sukrutha, S. K., & Janakiraman, S. (2014) · ePrints@Bangalore University (Bangalore University)
Ahmadian-Attari, M. M., Noorbala, A. A., Khoshdel, A., Kamalinejad, M., & Taghva, A. (2015) · Journal of Evidence-Based Complementary & Alternative Medicine · doi:10.1177/2156587215614703
Omega-3 Fatty Acids for Major Depressive Disorder: A Systematic Review
Newberry, S. J., Hempel, S., Booth, M. S., Ewing, B. A., Maher, A. R., O’Hanlon, C. E., Sloan, J., Vaughan, C., Dudley, W., Shanman, R., et al. (2015) · RAND Corporation eBooks · doi:10.7249/rr1079 · Cited by 3
Kann man schlechte Laune einfach wegessen
Schmiedel, V. (2016) · Erfahrungsheilkunde · doi:10.1055/s-0041-109259
“In dieser Studie unter-suchten May et al. [6] According to epidemiological studies, the risk of depression in good supply is low.”
InfluentialAntidepressant Therapy for Depression: An Update
Gupta, D., & Mahesh, R. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_17
Jeremiah, O. J. (2018) · Journal of Neurology & Neurophysiology · doi:10.4172/2155-9562-c5-074
El Baz, A. H. (2017) · Al-Azhar Journal of Pharmaceutical Sciences/Al-Azhar Journal of Pharmaceutical Sciences · doi:10.21608/ajps.2017.28463
Baz, A., Zaki, M. A., Wakeel, L. M. E., & M, E.-S. T. (2018) · The Egyptian Journal of Hospital Medicine · doi:10.12816/ejhm.2018.9798
El Baz, A. H., Wakeel, E., M, E.-S. T., & Zaki, M. A. (2019) · Journal of Food and Nutrition Research · doi:10.12691/jfnr-7-12-1
“The use of omega-3 polyunsaturated fatty acids (PUFAs) for treatment of depression is a potential option [5].”
BackgroundInfluentialEl Baz, A. H., Zaki, M. A., Wakeel, E., & M, E.-S. T. (2018) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2018.9798
n-3 PUFAs for depression: treatment effect or absence-of-placebo effect?
Memarpouri, A., van der Does, W. A. J., & Molendijk, M. L. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02072-z · Cited by 1
“Firstly, in contrast with their stated inclusion criteria, the data from 2 trials [2, 3] did not include an inert placebo arm.”
ResultCurrent Treatments for Depression
Fava, M., & Krystal, J. H. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197640654.003.0034
The role of nutraceuticals of natural origin in the treatment of depressive disorders
Sęk, M., Galasińska, I., Hajduk-Maślak, K., Michalik, B., Skóra, A., & Zając, D. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.82.60309
“These findings highlight the potential role of n-3 PUFAs as an adjunct to antidepressants [20].”
Metadata
- Authors
- Gertsik, L., Poland, R. E., Bresee, C., & Rapaport, M. H.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Meharry Medical College (US)
- Corresponding author
- Gertsik, Lev
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2012-02
- Volume
- 32
- Issue
- 1
- Pages
- 61-64
- ISSN
- 0271-0749 (ISSN-L)
- PMC
- PMC3375825
- OpenAlex
- W2069184109
- Semantic Scholar
- 1baeee66cc47765e9086c7363078b259186a30f9
- Cited by
- 162
- References
- 37
- Citations by year
- 2025: 5 · 2024: 6 · 2023: 14 · 2022: 6 · 2021: 6 · 2020: 9 · 2019: 13 · 2018: 9 · 2017: 17 · 2016: 21 · 2015: 22 · 2014: 10 · 2013: 19 · 2012: 5
- FWCI
- 10.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000124)
- National Center for Research Resources (U54RR026140, M01RR000425)
- National Center for Advancing Translational Sciences
- National Institute on Minority Health and Health Disparities (U54MD007593)
- National Center for Complementary and Integrative Health (R21AT001077)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- omega-3 fatty acids, citalopram, major depressive disorder, combination therapy, eicosapentaenoic acid, docosahexaenoic acid, selective serotonin reuptake inhibitors, antidepressant response, olive oil placebo
- MeSH terms
- Adult, Depressive Disorder, Major, Major Depressive Disorder, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Citalopram, Fatty Acids, Omega-3, Treatment Outcome, Antidepressive Agents, Second-Generation, Dietary Supplements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.